Search for content, post, videos

Capitainer and Attana sign collaboration agreement

Attana Capitainer collaborate

The two companies have signed an agreement with the goal of offering broader and more patient-centric blood sampling solutions for the Attana AVATM system starting with COVID-19 immune profiling.

Since November 2021, Attana has been performing comparative studies of finger stick capillary blood samples simultaneously collected by both test tubes and Capitainer qDBS cards (quantitative dried blood spot) for analysis in Attana’s AVATM system. These serological studies have shown high specificity and sensitivity with good reproducibility for both sampling methods, states the companies.

An expanded patient study within the framework of Attana’s ongoing Covid study

Because of the ease of use and sampling accuracy, Attana and Capitainer have now initiated a collaboration to clinically validate Capitainer’s qDBS cards in combination with the Attana CE IVD-marked SARS-CoV-2 Immunoassay kit. In the coming months, the parties intend to perform an expanded patient study within the framework of Attana’s ongoing Covid study with Linnaeus University and Region Kalmar. The objective is to expand Attana’s CE IVD marking to include sampling of capillary blood (qDBS and test tubes), in addition to current serum samples.

“The need for remote sampling will continue to grow in the coming years within clinical diagnostics, drug development, as well as in academic research fields such as immunology and virology.”

“During the pandemic, standard diagnostic sampling has been particularly challenging in patient studies which call for multiple testing, often also across wide geographic areas. In addition to an ongoing need for COVID-19 immunity and vaccine efficacy studies, there is much to suggest that the need for remote sampling will continue to grow in the coming years within clinical diagnostics, drug development, as well as in academic research fields such as immunology and virology. The Attana AVA system in combination with Capitainer qDBS will be able to offer our customers and their patients high quality diagnostic analyses in a wider scope of studies than possible today,” says Samir Fostock, Head of Attana Diagnostics.

“This collaboration will help to make these new analyses available to patients irrespective of how far they live from a laboratory.”

“During the pandemic our sampling solution was validated in several studies and there is a large demand for new analyses which are performed using small sample volumes. The Attana AVA system offers advanced diagnostics and is an ideal fit with Capitainer’s ambition to develop analysis solutions from samples that can be taken at home. This collaboration will help to make these new analyses available to patients irrespective of how far they live from a laboratory,” says Mikael Ström, Business Development Manager Capitainer.

Photo: Capitainer